BridgeMD
New treatment option for Lung Cancer
Official title Ventilation Imaging to Improve the Quality of Life for Patients With Lung Cancer Treated With Radiation Therapy
ClinicalTrials.gov ID: NCT06127654
What this study is testing
- What it's testing
- This research project is testing a new treatment planning method for patients with lung cancer who will be treated with radiation therapy. This new method is called Computed Tomography (CT) ventilation imaging.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Aged 18 years or older.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- Histologically proven non-small cell lung cancer.
- Stage 3 as determined using the IASLC (International Association for the Study of Lung Cancer) 8th edition lung cancer staging guidelines.
- To be treated with curative intent external beam radiotherapy (60 Gy in 30 treatments or 55 Gy in 20 treatments) +/- concurrent chemotherapy and...
You likely can't join if
- Serious medical comorbidities that may contraindicate curative radiotherapy.
- Inability to attend full course of radiotherapy or follow-up visits.
- A current or former diagnosis of interstitial lung disease.
- Prior history of lung cancer within 5 years.
- Prior thoracic radiotherapy at any time.
- Prior surgery for this cancer within a year.
See the full eligibility criteria
- Aged 18 years or older.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- Histologically proven non-small cell lung cancer.
- Stage 3 as determined using the IASLC (International Association for the Study of Lung Cancer) 8th edition lung cancer staging guidelines.
- To be treated with curative intent external beam radiotherapy (60 Gy in 30 treatments or 55 Gy in 20 treatments) +/- concurrent chemotherapy and adjuvant PD1/PD-L1 inhibitors.
- Whole body Positron Emission Tomography (PET) scan within 8 weeks of registration.
- Pulmonary function tests within 8 weeks of registration.
- Willingness to give written informed consent.
- Willingness to comply with the study procedures and visit requirements.
- Available for follow up for a minimum of 12 months and up to 3 years. Post-includes the results of a Quality of Life (QoL) assessment and treatment plan assessment, neither of which are known prior to consent. The...
- Functional Assessment of Cancer Therapy - Lung (FACT-L) Trial Outcome Index (TOI) score of ≥5, the clinically meaningful difference
- The standard treatment plan shows that at least 16% of volume of the lungs (minus the Gross Tumour Volume (GTV)) will receive more than 20 Gy. This criterion is based on the difference in pneumonitis risk between...
- Serious medical comorbidities that may contraindicate curative radiotherapy.
- Inability to attend full course of radiotherapy or follow-up visits.
- A current or former diagnosis of interstitial lung disease.
- Prior history of lung cancer within 5 years.
- Prior thoracic radiotherapy at any time.
- Prior surgery for this cancer within a year.
- Prior chemotherapy for this cancer.
- Pregnant or lactating women.
The study team makes the final eligibility decision.
Where it's taking place
- Liverpool, New South Wales, Australia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Liverpool, New South Wales, Australia. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.